Hopital Saint Eloi

Hopital Saint Eloi’s hepato‑gastro‑enterology department leads research on liver disease, biliary cancers and inflammatory bowel disorders, aiming to improve treatment outcomes and quality of life for patients.

• Hepatocellular carcinoma
• Advanced biliary tract cancers
• Ulcerative colitis
• Crohn's disease
• Non‑alcoholic steatohepatitis (NASH)
• Metabolic dysfunction‑associated steatohepatitis (MASH)
• Chronic hepatitis D infection
• Esophageal achalasia

The site currently supports 28 clinical trials with a team of 33 investigators, fostering collaborations across Europe.

Studies at the hospital target blood‑derived malignancies, exploring novel immunotherapies and targeted agents to enhance survival in patients with aggressive cancers.

• Acute myeloid leukemia
• Myelodysplastic syndrome
• Mantle cell lymphoma
• Non‑Hodgkin lymphoma
• Chronic lymphocytic leukemia
• Richter’s syndrome
• Relapsed/refractory marginal zone lymphoma
• B‑cell NHL

Researchers are evaluating safety and efficacy of bispecific antibodies and cellular therapies to address unmet needs in these diseases.

The department investigates immune‑mediated gastrointestinal conditions, testing biologic agents that modulate inflammatory pathways to achieve remission and reduce disease burden.

• Moderately to severely active ulcerative colitis
• Moderately to severely active Crohn's disease
• Idiopathic hypersomnia

Ongoing trials compare new monoclonal antibodies with standard therapies, seeking faster symptom control and long‑term safety.

A broad oncology program examines solid tumors such as melanoma and renal cell carcinoma, integrating checkpoint inhibitors and targeted drugs to prevent recurrence after surgery.

• Hepatocellular carcinoma
• Melanoma
• Renal cell carcinoma
• Lymphatic malformations associated with PIK3CA mutation
• Advanced biliary tract cancers

The aim is to identify regimens that improve overall survival while maintaining quality of life for cancer survivors.

Clinical work includes evaluating oral anticoagulants to lower the risk of major adverse cardiac events in patients who have experienced a heart attack, focusing on safety and reduction of recurrent events.

• Acute coronary syndrome

The trial design measures cardiovascular death, myocardial infarction and ischemic stroke as composite outcomes.

Research on chronic viral hepatitis aims to assess long‑term liver outcomes with novel antivirals, addressing a key public‑health challenge in the region.

• Chronic hepatitis D infection

Participants are monitored for liver‑related events to determine the therapeutic benefit of emerging treatments.

The site conducts trials on metabolic liver disorders, testing agents that may resolve steatohepatitis and reverse fibrosis, thereby preventing progression to cirrhosis.

• Non‑alcoholic steatohepatitis (NASH)
• Metabolic dysfunction‑associated steatohepatitis (MASH)
• Fibrosis

Endpoints include histological improvement and reduction of liver‑related mortality.

A focus on public health evaluates procedural interventions and post‑procedure medication strategies to reduce complications and improve patient safety in everyday clinical practice.

• Acid reflux management after POEM for esophageal achalasia
• Health outcomes following endoscopic myotomy

Findings aim to guide best practices for clinicians and inform health‑policy decisions in the wider community.